Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 1997

View Archived Issues

NIH seeks licensees for antispasmodic immunotoxin

Licenses offered for vasospasm therapy

NIH seeks licensees for method of treating allergies and HIV

Method of treating allergies and HIV offered for licensing

NIH seeks licensees for therapeutic/diagnostic HAV receptor

Antiviral nucleoside analogues available for licensing

CD40 ligands and MAbs offered for licensing

NIH seeks licensees for cancer vaccines

Licensees sought for recombinant laminin receptors

Transcriptional cofactor offered by NIH

DNA sequencing technology available for licensing

Medco's cardiovascular evaluation agent receives European approval

Correlation between asthma and IL-10

Gene vaccination shows potential against allergy

Phase I results with rhIL-4 receptor

Long-term use of recombinant IFN-gamma evaluated

Acorda and Elan to collaborate on spinal cord injury treatment

GalaGen's Diffistat-G advances through phase I

Role of IL-5 in asthma

IL-15 enhancement of neonatal defenses

Merck's Fosamax earns recommendation

Combination beta-agonist/corticosteroid therapy beneficial in asthma

Novo Nordisk's growth hormone now available in 67 countries

Efficacy of hydoxychloroquine in asthma

Review date set for Sonus ultrasound contrast agent

CytoTherapeutics and Cognetix collaborate on CNS R&D

Provir progresses through clinical trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.